GLP-1 receptor agonist
Semaglutide is a GLP-1 receptor agonist available in several FDA-approved injections and tablets. The evidence base spans weight management, type 2 diabetes, cardiovascular outcomes, chronic kidney disease, and a defined MASH population—but the brands and formulations are not interchangeable.
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Research at a glance
Depth and confidence summarize the research record—not effectiveness, safety, or a recommendation.
Large trials and approved products cover injectable and oral formulations across several metabolic outcomes.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Weight, cardiovascular, kidney, diabetes, pediatric-obesity, and MASH findings are supported by large controlled programs in defined populations.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not a suggested amount.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Ozempic, Wegovy, and investigational high-dose programs cannot be flattened into one generic schedule. Results belong to the tested product, population, and amount. Amounts shown describe cited research exposure—not a dosage recommendation.
Practical starting point
Common goals and questions—not recommendations or promises of benefit.
The overview, studies, and source ledger below explain what supports each label—and where the evidence stops.
What the evidence says
Multiple large randomized Phase 3 trials and outcomes trials support defined weight, cardiovascular, kidney, diabetes, pediatric-obesity, and MASH findings. SELECT enrolled 17,604 participants, and FLOW enrolled 3,533.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Long-term comparative outcomes across newer formulations and doses, rare-event characterization at population scale, and whether trial results extend to unstudied populations or unapproved products.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
The evidence story
Importance shows how much an item changes the evidence story. Quality shows how much confidence the design deserves. A strong negative study can score highly on both.
Importance and quality answer different questions. A rigorous study can be highly important even when it challenges a popular claim.
Mean weight change was -18.7% with 7.2 mg, -15.6% with 2.4 mg, and -3.9% with placebo. Gastrointestinal events and altered skin sensation were more common at 7.2 mg.
Mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide; mean waist change was -18.4 cm and -13.0 cm.
MASH resolution without worsening fibrosis occurred in 62.9% versus 34.3%; fibrosis improvement without worsening MASH occurred in 36.8% versus 22.4%.
The primary kidney-and-cardiovascular composite occurred less often with semaglutide than placebo (hazard ratio 0.76).
A major cardiovascular event occurred in 6.5% with semaglutide and 8.0% with placebo (hazard ratio 0.80). Discontinuation from adverse events was more frequent with semaglutide.
Administration and handling
Current U.S. labels describe weekly subcutaneous injections and daily oral tablets. Oral products have fasting and water-volume rules, and the brands, tablets, injections, strengths, indications, and switching schedules are not automatically interchangeable. Product labels—not a generic semaglutide schedule—are the controlling source. This is educational label context, not an individualized dose recommendation.
FDA-approved semaglutide products are ready-to-use injections or tablets and do not require reconstitution. Injection refrigeration and permitted room-temperature periods vary by presentation; tablets have label-specific room-temperature and moisture-protection instructions. These directions do not establish handling for unapproved compounded, lyophilized, or vendor-supplied material.
Primary-source ledger
2026-06-18
2026-06-01
2026-01-30
2025-09-14 · PMID 40961952 · NCT05646706 · DOI 10.1016/S2213-8587(25)00226-8
2025-05-11 · PMID 40353578 · NCT05822830 · DOI 10.1056/NEJMoa2416394
2025-04-30 · PMID 40305708 · NCT04822181 · DOI 10.1056/NEJMoa2413258
2024-05-24 · PMID 38785209 · NCT03819153 · DOI 10.1056/NEJMoa2403347
2023-11-11 · PMID 37952131 · NCT03574597 · DOI 10.1056/NEJMoa2307563
2022-11-02 · PMID 36322838 · NCT04102189 · DOI 10.1056/NEJMoa2208601
2021-02-10 · PMID 33567185 · NCT03548935 · DOI 10.1056/NEJMoa2032183
2021-01-03 · PMID 33269530 · NCT03767582 · DOI 10.1111/dom.14280